Skip to main content
Top
Published in: Trials 1/2018

Open Access 01-12-2018 | Research

Partial factorial trials: comparing methods for statistical analysis and economic evaluation

Authors: Helen A. Dakin, Alastair M. Gray, Graeme S. MacLennan, Richard W. Morris, David W. Murray

Published in: Trials | Issue 1/2018

Login to get access

Abstract

Background

Partial factorial trials compare two or more pairs of treatments on overlapping patient groups, randomising some (but not all) patients to more than one comparison. The aims of this research were to compare different methods for conducting and analysing economic evaluations on partial factorial trials and assess the implications of considering factors simultaneously rather than drawing independent conclusions about each comparison.

Methods

We estimated total costs and quality-adjusted life years (QALYs) within 10 years of surgery for 2252 patients in the Knee Arthroplasty Trial who were randomised to one or more comparisons of different surgical types. We compared three analytical methods: an “at-the-margins” analysis including all patients randomised to each comparison (assuming no interaction); an “inside-the-table” analysis that included interactions but focused on those patients randomised to two comparisons; and a Bayesian vetted bootstrap, which used results from patients randomised to one comparison as priors when estimating outcomes for patients randomised to two comparisons. Outcomes comprised incremental costs, QALYs and net benefits.

Results

Qualitative interactions were observed for costs, QALYs and net benefits. Bayesian bootstrapping generally produced smaller standard errors than inside-the-table analysis and gave conclusions that were consistent with at-the-margins analysis, while allowing for these interactions. By contrast, inside-the-table gave different conclusions about which intervention had the highest net benefits compared with other analyses.

Conclusions

All analyses of partial factorial trials should explore interactions and assess whether results are sensitive to assumptions about interactions, either as a primary analysis or as a sensitivity analysis. For partial factorial trials closely mirroring routine clinical practice, at-the-margins analysis may provide a reasonable estimate of average costs and benefits for the whole trial population, even in the presence of interactions. However, such conclusions will be misleading if there are large interactions or if the proportion of patients allocated to different treatments differs markedly from what occurs in clinical practice. The Bayesian bootstrap provides an alternative to at-the-margins analysis for analysing clinical or economic endpoints from partial factorial trials, which allows for interactions while making use of the whole sample. The same techniques could be applied to analyses of clinical endpoints.

Trial registration

ISRCTN, ISRCTN45837371. Registered on 25 April 2003.
Appendix
Available only for authorised users
Footnotes
1
We follow the definition used by [13], although the term “partial factorial trials” is also used to describe “incomplete factorial trials” in which all experimental units are randomised to a subset of the possible combinations of factors [12, 29].
 
2
A fourth factor was also evaluated [3], comparing total versus unicompartmental knee replacement, but it is not discussed here since it did not overlap with other comparisons and stopped early due to difficulties in recruiting participants.
 
3
This number of bootstraps was chosen for pragmatic reasons and ensured that after rejection sampling there were at least 6000 bootstraps included in the analysis at a £20,000/QALY ceiling ratio, although the exact number of bootstraps included in the calculation of CEACs varied with ceiling ratio.
 
4
Notably, this analysis provides a real-life example of the situation identified hypothetically previously [30, 31], in which NMB differs significantly (p = 0.96 on a one-tailed test) between treatments, despite non-significant differences in both costs and effects.
 
5
In principle, we could reduce bias by adjusting for observed confounders (e.g. using propensity scores or genetic matching [32, 33]), although the subgroup approach would remain vulnerable to bias from unobserved confounders.
 
Literature
2.
go back to reference The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61–109.CrossRef The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61–109.CrossRef
3.
go back to reference Murray DW, MacLennan GS, Breeman S, Dakin HA, Johnston L, Campbell MK, et al. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of different knee prostheses: the Knee Arthroplasty Trial (KAT). Health Technol Assess. 2014;18 https://doi.org/10.3310/hta18190. Murray DW, MacLennan GS, Breeman S, Dakin HA, Johnston L, Campbell MK, et al. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of different knee prostheses: the Knee Arthroplasty Trial (KAT). Health Technol Assess. 2014;18 https://​doi.​org/​10.​3310/​hta18190.
4.
go back to reference UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34:877–90.CrossRef UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34:877–90.CrossRef
9.
go back to reference Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Handbooks in health economic evaluation. Oxford: Oxford University Press; 2007. Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Handbooks in health economic evaluation. Oxford: Oxford University Press; 2007.
12.
go back to reference Brittain E, Wittes J. Factorial designs in clinical trials: the effects of non-compliance and subadditivity. Stat Med. 1989;8:161–71.CrossRefPubMed Brittain E, Wittes J. Factorial designs in clinical trials: the effects of non-compliance and subadditivity. Stat Med. 1989;8:161–71.CrossRefPubMed
13.
go back to reference Hung HM. Two-stage tests for studying monotherapy and combination therapy in two-by-two factorial trials. Stat Med. 1993;12:645–60.CrossRefPubMed Hung HM. Two-stage tests for studying monotherapy and combination therapy in two-by-two factorial trials. Stat Med. 1993;12:645–60.CrossRefPubMed
15.
go back to reference Cox DR. Planning of experiments, Wiley classics edition published 1992. New York: Wiley; 1958. Cox DR. Planning of experiments, Wiley classics edition published 1992. New York: Wiley; 1958.
16.
go back to reference Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. Applied linear statistical models. 4th ed. Chicago: Irwin; 1996. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W. Applied linear statistical models. 4th ed. Chicago: Irwin; 1996.
20.
go back to reference Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117.CrossRefPubMed Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117.CrossRefPubMed
21.
go back to reference Cui L, Hung HM, Wang SJ, Tsong Y. Issues related to subgroup analysis in clinical trials. J Biopharm Stat. 2002;12:347–58.CrossRefPubMed Cui L, Hung HM, Wang SJ, Tsong Y. Issues related to subgroup analysis in clinical trials. J Biopharm Stat. 2002;12:347–58.CrossRefPubMed
27.
go back to reference Simon R, Freedman LS. Bayesian design and analysis of two × two factorial clinical trials. Biometrics. 1997;53:456–64.CrossRefPubMed Simon R, Freedman LS. Bayesian design and analysis of two × two factorial clinical trials. Biometrics. 1997;53:456–64.CrossRefPubMed
28.
go back to reference Welton NJ, Ades AE, Caldwell DM, Peters TJ. Research prioritization based on expected value of partial perfect information: a case-study on interventions to increase uptake of breast cancer screening. J R Stat Soc A. 2008;171:807–41.CrossRef Welton NJ, Ades AE, Caldwell DM, Peters TJ. Research prioritization based on expected value of partial perfect information: a case-study on interventions to increase uptake of breast cancer screening. J R Stat Soc A. 2008;171:807–41.CrossRef
29.
go back to reference Meinhert CL. Clinical trials: design, conduct, and analysis. Monographs in epidemiology and biostatistics. Oxford: Oxford University Press; 1986.CrossRef Meinhert CL. Clinical trials: design, conduct, and analysis. Monographs in epidemiology and biostatistics. Oxford: Oxford University Press; 1986.CrossRef
31.
go back to reference Gray A, Clarke P, Wolstenholme J, Wordsworth S. Chapter 11: presenting cost-effectiveness results. Applied methods of cost-effectiveness analysis. In: Health care handbooks in health economic evaluation series. Oxford: Oxford University Press; 2011. Gray A, Clarke P, Wolstenholme J, Wordsworth S. Chapter 11: presenting cost-effectiveness results. Applied methods of cost-effectiveness analysis. In: Health care handbooks in health economic evaluation series. Oxford: Oxford University Press; 2011.
32.
go back to reference Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw. 2011;42:1–52.CrossRef Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw. 2011;42:1–52.CrossRef
Metadata
Title
Partial factorial trials: comparing methods for statistical analysis and economic evaluation
Authors
Helen A. Dakin
Alastair M. Gray
Graeme S. MacLennan
Richard W. Morris
David W. Murray
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Trials / Issue 1/2018
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-018-2818-x

Other articles of this Issue 1/2018

Trials 1/2018 Go to the issue